BeiGene is an innovative Chinese oncology R&D company focused on discovering, developing and commercializing targeted and immune-oncology therapeutics through a novel translational research platform that leverages our strong internal oncology biology expertise with unique access to large number of patient-derived tumor biopsies. With a team of 150 scientists and staff, its pipeline is comprised of novel oral small molecules and monoclonal antibodies for cancer, including a second-generation BRAF inhibitor in Phase I, a best-in-class PARP inhibitor in Phase I ,a best-in-class BTK inhibitor in Phase I. Global phase 2/3 trials are expected starting from 2015.Besides that,2 to 3 small molecule and immune oncology mAb drugs are expected to enter clinical trial each year. For more information, please visit our website at www.beigene.com
百济神州（北京）生物科技有限公司是一家位于北京市中关村生命科学园区的中国生物技术与新药创制公司，致力于研究和开发包括新型化学小分子和生物大分子在内的创新抗癌药物。百济通过自主开发其中国实验室发现的新药，以及同制药公司合作伙伴合作授权共同开发在研新药，以满足中国和亚洲的癌症患者未能满足的医疗需求。百济正在创建一个坚实的生物标志物和生物信息学平台，用于识别癌症患者中有可能受益于相关药物或治疗方法的病人亚群，并通过研究药物的敏感性和靶标分子之间的关系来研制出更有效和更安全的靶向创新药物。更多信息，请访问www.beigene.com.